|
Myasthenia Gravis |
|---|---|
| รหัสดีโอไอ | |
| Creator | Winita Fowsantear |
| Title | Myasthenia Gravis |
| Contributor | Sutthiwan Thammawat, Jinatta Jittiwat |
| Publisher | Faculty of Pharmaceutical Sciences KKU MSU UBU |
| Publication Year | 2561 |
| Journal Title | Isan Journal of Pharmaceutical Sciences |
| Journal Vol. | 14 |
| Journal No. | 2 |
| Page no. | 16-25 |
| Keyword | Myasthenia gravis, autoimmune disease, neuromuscular junction, autoantibody, nicotinic acetylcholine receptor, acetylcholine |
| URL Website | https://tci-thaijo.org/index.php/IJPS |
| Website title | Isan Journal ofPharmaceutical Sciences, IJPS |
| ISSN | 19050852 |
| Abstract | Myasthenia gravis (MG) is an autoimmune disease that affects the neuromuscular junction. In Thailand, MG affects approximately 2.17 patients per 100,000 population. MG is primary caused by autoantibodies directing towards the nicotinic acetylcholine receptors at the post synaptic membrane leading to muscle weakness. The clinical characteristic signs and symptoms of myasthenia gravis are ptosis, diplopia, weakness in chewing, difficult in swallowing and fluctuating levels of skeletal muscle weakness. The severity of weakness and fatigability fluctuates during the day, usually being least severe in the morning and worse as the day progress, especially during exercise or continuous repetitive motion with at least partially restored strength after period of rest. There are two approaches for management of MG based on the pathophysiology of this disease. The first treatment is by increasing the amount of acetylcholine that is available to bind with the nicotinic acetylcholine receptor at postsynaptic membrane using an acetylcholinesterase inhibitor agent. The second approach is by using immunosuppressive medications that can reduce the binding of nicotinic acetylcholine receptors by antibodies. |
